August 2026 Research Update

This month added a clearer (but still early) picture that TNF blockers, especially adalimumab, can line up with improved symptoms in children with CNO/CRMO, and sometimes with lesions disappearing on MRI. The evidence here is not from head-to-head trials, but the pattern across reports is that pain and activity limits can improve, while MRI is increasingly used to track whether bone inflammation is truly quiet. Side effects and treatment changes also appeared in these reports, reminding readers that real-world courses can involve adjustments over time. [1] [2]

In a 9-child single-center series using adalimumab, most patients reached clinical remission, and about half reached radiographic remission with complete MRI lesion resolution by follow-up. A smaller group reached what the authors called complete remission, meaning symptoms and MRI findings both settled down, while one child stopped TNF therapy because of a severe psoriasis-like skin reaction and later reached remission on other medicines. This strengthens the month-to-month message that MRI changes do not always move in lockstep with symptoms, so both were tracked. [1]

Safety signals in this small series were mainly skin-related, with several children developing a psoriasiform (psoriasis-like) rash while on adalimumab, and treatment was adjusted rather than requiring hospital-level care. A separate adolescent case also reported good clinical and imaging response to TNF blockers, but the patient switched from adalimumab to etanercept and later to methotrexate because of side effects and anti-drug antibodies (immune proteins that can reduce a drug's effect). Together, these reports show both potential symptom control and the practical reality that treatments may need to be changed for tolerability or loss of response. [1] [2]

For patients and caregivers, these studies mainly add context about what has been seen in small real-world groups: TNF blockers like adalimumab can coincide with major symptom improvement, and sometimes with MRI-confirmed quieting of bone inflammation. This does not settle how well TNF blockers work compared with other options because there was no comparison group, but it does help explain why some care teams pay close attention to both symptoms and imaging over time. What remains uncertain is how often MRI remission happens across broader groups, and which patients are most likely to need treatment switches because of side effects or anti-drug antibodies. [1] [2]

This month focused strongly on how to measure CNO/CRMO in a way that matches lived experience and can be compared across studies. One project proposed practical definitions for minimal disease activity, flare, and a meaningful improvement threshold, with MRI findings playing a central role alongside pain and clinician assessments. Another study showed that patient-reported surveys for pain and mobility move in the expected direction when disease status changes, supporting their use for tracking daily impact. [3] [4]

In international registry data paired with expert and patient/caregiver input, minimal disease activity was defined in a strict way that required no active MRI lesions, no MRI-confirmed sacroiliitis (inflammation of the sacroiliac joints), and no active clinical bone lesions. Flare classification was most influenced by pain and the number of MRI lesions, with spine or sacroiliac involvement leaning toward flare. The authors emphasized these definitions are proposed for future studies and still need external validation. [3]

In a separate longitudinal registry of 184 children, PROMIS pediatric measures (standard questionnaires) showed meaningful links with both clinician-rated disease activity and how families rated disease status. The strongest and most consistent measures for CNO/CRMO were mobility, pain behavior, and pain interference, and these scores shifted over time in ways that matched reported status changes. In a small subgroup where a clinical disease activity score improved by at least 3 points, PROMIS scores for mobility and pain also improved, supporting the idea that these surveys can capture changes that matter in day-to-day life. [4]

For patients, this body of work is mainly about making CNO/CRMO easier to track and compare, rather than testing a new treatment. It helps clarify that research groups are moving toward shared definitions of what "doing well" and "flaring" mean, and that both MRI findings and pain-related daily limitations are considered important parts of that picture. What remains uncertain is how these proposed definitions will perform in other settings, especially where whole-body MRI is not routinely available. These tools may matter more over time, because they can make future studies and registries easier to interpret and may improve consistency in how progress is described. [3] [4]

This month, case-based reports reinforced that CNO/CRMO is often recognized only after a careful process of ruling out other serious explanations for bone lesions. Across ages, imaging can look alarming or confusing, especially when there is a single active lesion or a history of cancer, and biopsy was used in several reports to confirm there was no infection or malignancy. These reports also showed that CNO/CRMO can be long-running and sometimes leave lasting effects on bones or growth, even when pain improves. [5] [6] [7] [8]

Several reports centered on the sternum, where pain or scan findings can raise concerns for other diagnoses. In an adult with a prior breast cancer history, a solitary sternal lesion was FDG-avid on PET/CT (a pattern that can resemble metastasis), but biopsy supported chronic nonbacterial osteomyelitis and follow-up MRI showed regression. A separate adolescent with sternal pain also underwent imaging and biopsy as part of diagnosis, illustrating why tissue confirmation can matter when the presentation is atypical or high-stakes. [5] [2]

Longer-term course and complications were highlighted in a pediatric case where recurrent disease episodes were followed by growth-plate injury and a measurable leg-length difference. An adult case followed for 8 years described migratory tibial lesions that flared and then regressed, with pain rising and falling alongside lesion activity, and partial pain relief during flares with anti-inflammatory treatment. An educational case also walked through how imaging and biopsy findings can help distinguish CRMO from bacterial osteomyelitis in a child. [6] [7] [8]

One broader pediatric genetics cohort also placed CNO/CRMO in the wider landscape of autoinflammatory conditions by reporting it as a small portion of diagnoses among children carrying a single MEFV gene variant. In that same cohort, some children initially diagnosed with other inflammatory diseases later developed familial Mediterranean fever during follow-up, showing how diagnoses in this space can shift over time. While this does not pinpoint a specific genetic cause for CNO/CRMO, it adds context that overlapping inflammatory labels can occur in real-world pediatric practice. [9]

For patients and caregivers, these reports mainly help set expectations about the diagnostic journey and the range of possible disease courses. They show that scans alone can sometimes resemble infection or cancer, so biopsy and follow-up imaging may be used to make the diagnosis safer and more confident, especially for a single lesion or in someone with a cancer history. They also highlight that repeated inflammation near growth areas can have lasting skeletal effects in some children, which is why long-term monitoring is often discussed in case-based literature, even when symptoms improve. What remains uncertain is how common these more serious bone or growth outcomes are, because case reports focus on unusual or instructive situations rather than typical experiences. [5] [6] [7] [8] [9]